Coronary artery bypass graft (CABG) off- or onpump revascularisation study

Submission date Prospectively registered Recruitment status 04/02/2008 No longer recruiting [X] Protocol [] Statistical analysis plan Registration date Overall study status 04/02/2008 Completed [X] Results Individual participant data **Last Edited** Condition category 03/04/2019 Circulatory System

Plain English summary of protocol

Not provided at time of registration

Study website

http://www.ccc.mcmaster.ca/coronary.htm

Contact information

Type(s)

Scientific

Contact name

Dr Andre Lamy

Contact details

Hamilton General Hospital 237 Barton St. E. McMaster Clinic Room 704 Hamilton, Ontario Canada L8L 2X2 +1 905 522 0175 lamya@mcmaster.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00463294

Secondary identifying numbers

MCT-85214; 5999

Study information

Scientific Title

Coronary artery bypass graft (CABG) off- or on-pump revascularisation study

Acronym

CORONARY

Study objectives

Primary hypothesis:

In patients undergoing coronary artery bypass graft (CABG) surgery, off-pump CABG surgery compared to on-pump CABG surgery reduces major clinical vascular events in the short term (30 days) and these benefits are maintained at long term (5 years).

Secondary hypothesis:

In patients undergoing CABG surgery, off-pump CABG surgery compared to on-pump CABG surgery reduces costs in the short term (30 days) and at long term (5 years).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from:

- 1. Canada: Research Ethics Board of Hamilton Health Sciences/McMaster University, Hamilton, Ontario on the 30th March 2007 (final approval for pilot) and 19th June 2007 (re-consent for long term follow-up) (ref: 06-045)
- 2. Brazil: Comite de Etica em Pesquisa, Institute Dante Pazzanese on the 6th November 2007 (ref: CEP 3581)
- 3. Colombia: Comité de Ética en Investigación , Fundacion Cardiovascular Del Oriente Colombiano, Floridablanca (SS) on the 23rd January 2008
- 4. France: Comité de Protection des Personnes, CHU-Hôpital Saint Jacques on the 26th June 2007 (ref: 07/446)
- 5. Turkey: Research Ethics Committee of Medical Faculty, Ankara University, Ankara on the 7th January 2008 (ref: 123-3353)
- 6. Chile: Gobierno De Chile, Servicio de Salud Metropolitano Oriente, Comité de Ética Científico, Santiago on the 20th January 2008
- 7. China: Ethics Committee FuWai Hospital, Beijing in May 2007
- 8. Czech Republic: Eticka Komise, Fakulni nemocnice Kralovske Vinohrady, Prague on the 9th January 2008
- 9. India: Ethics Committee All India Institute of Medical Sciences, Delhi on the 10th April 2008 10. Italy: Comitao Etico Intraziendale, Azienda Ospedaliera S. Croce e Carle, Cuneo on the 4th April 2008
- 11. Poland: Niezna Komisia Bioetyczna, Akademia Medyczna, Gdansk on the 15th May 2008
- 12. Ukraine: Komitet z medicnoi etiki, M.M. Amosov Government Facility, National Institute of Cardio-vascular Surgery on the 26th June 2008
- 13: United Kingdom: MREC approved (ref: 08/H0604/48)

Ethics approval pending as of 26/04/2010 from:

- 14. Slovak Republic
- 15. Argentina
- 16. Netherlands

Study design

International unblinded multicentre two arm randomised parallel surgical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Coronary artery disease requiring isolated coronary artery bypass graft (CABG)

Interventions

Coronary artery bypass graft (CABG) surgery with or without cardio-pulmonary bypass (CPB) machine:

- 1. Experimental group: CABG without use of CPB
- 2. Control group: CABG with the use of CPB

Contact for public queries (except for UK component):

Kamil Malikov

Email: kmalikov@ccc.mcmaster.ca

Parvez Khatib

Email: parvez@ccc.mcmaster.ca

Contact details for UK component:

Ms Carol Wallis

carol.wallis@nds.ox.ac.uk

Sponsor details for UK component:

University of Oxford (UK)

University Offices

Wellington Square

Oxford

OX1 2JD

United Kingdom

http://www.ox.ac.uk/

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

- 1. The occurrence of the composite of total mortality, stroke, nonfatal myocardial infarction [MI], or new renal failure at 30 days post CABG surgery
- 2. The occurrence of the composite of total mortality, stroke, nonfatal MI, new renal failure, or repeat coronary revascularisation (i.e. coronary artery bypass surgery or percutaneous coronary intervention) over 5 years after randomisation

Secondary outcome measures

- 1. The assessment of total costs and resources consumption at 30 days after CABG surgery
- 2. The assessment of total costs and resources consumption at 5 years after CABG surgery

Overall study start date

01/10/2007

Completion date

31/05/2014

Eligibility

Key inclusion criteria

- 1. Require isolated CABG with median sternotomy
- 2. Provide written informed consent
- 3. 21 years of age and older, either sex
- 4. Have one risk factor or more:
- 4.1. Greater than or equal to 70 years age
- 4.2. Peripheral vascular disease (previous peripheral bypass or amputation or ankle brachial index [ABI] less than 0.80)
- 4.3. Cerebrovascular disease (history of stroke, transient ischaemic attack [TIA], carotid stenosis greater than 70%)
- 4.4. Renal insufficiency (creatinine above upper limit of normal)
- 4.5. Greater than 60 years of age with one of the following:
- 4.5.1. Diabetes (oral hypoglycaemic agent and/or insulin)
- 4.5.2. Urgent revascularisation (waiting in hospital)
- 4.5.3. Left ventricular ejection fraction less than 35%
- 4.5.4. Current or recent smokers (within 1 year of randomisation)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Planned Sample Size: 4700; UK Sample Size: 250

Key exclusion criteria

- 1. Concomitant cardiac procedure associated with CABG
- 2. Contra-indications to off-pump CABG or on-pump CABG (calcified aorta, intramuscular left anterior descending [LAD], calcified coronaries, small target vessels)
- 3. Concomitant life-threatening disease likely to limit life expectancy to less than 2 years
- 4. Prior enrolment in this trial
- 5. Emergency CABG surgery (immediate revascularisation for haemodynamic instability)
- 6. Redo CABG

Ukraine

Date	of	first	enro	lment
01/10	1/2	007		

	01/10/2007
	Date of final enrolment 31/05/2014
L	Locations
	Countries of recruitment Argentina
E	Brazil
C	Canada
C	Chile
C	China
C	Colombia
C	Czech Republic
F	France
lı	ndia
I	taly
١	Netherlands
F	Poland
S	Slovakia
T	Гürkiye

United Kingdom

Study participating centre Hamilton General Hospital Hamilton, Ontario Canada L8L 2X2

Sponsor information

Organisation

Population Health Research Institute (PHRI) (Canada)

Sponsor details

McMaster University, General Site 237 Barton Street East Hamilton, Ontario Canada L8L 2X2

Sponsor type

Research organisation

Website

http://www.ccc.mcmaster.ca/

ROR

https://ror.org/03kwaeq96

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-85214)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2012		Yes	No
Protocol article	sub-study protocol	18/04/2012		Yes	No
Results article	results	19/04/2012		Yes	No
Results article	results	28/03/2013		Yes	No
Results article	results	04/06/2014		Yes	No
Results article	results	01/11/2014		Yes	No
Results article	results	15/12/2016		Yes	No